alpha-Copaen-11-ol is a sesquiterpene alcohol documented in agarwood and a smaller number of other essential-oil profiles. In the AromaForge archive it is best supported as an identity and occurrence marker, especially in Aquilaria agarwood oil, where it appears at moderate-to-high levels. Public constituent-specific bioactivity evidence is limited and leans heavily on in-silico or mixed-fraction work rather than isolated human or animal studies, so archive summaries should keep claims conservative.
Chemical identity and composition
NIST and PubChem identify alpha-copaen-11-ol as C15H24O. In the archive's agarwood record, alpha-copaen-11-ol was reported at 4.06-10.22% in hydrodistilled Aquilaria sinensis oils, making it one of the more prominent oxygenated sesquiterpenes in that profile.
Aroma and practical use
- Use the recorded woody, sweet, spicy descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
occurrence in agarwood
A full-text agarwood composition study reported alpha-copaen-11-ol at 4.06% and 10.22% in chemically stimulated and wild Aquilaria sinensis oils, respectively.
Measured: relative abundance
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
alpha amylase related research
An abstracted Sabina chinensis study reported alpha-copaen-11-ol among the lower-energy docked constituents against alpha-amylase, but the measured enzyme inhibition was attributed to the whole essential oil rather than isolated alpha-copaen-11-ol.
Measured: whole-oil inhibition and constituent docking score
This experimental finding does not establish benefit, dose or safety in people using this blend.
other occurrence data
A Journal of Essential Oil Research paper on Adesmia boronioides reported alpha-copaen-11-ol at 8.5% and described the oil as sweet-woody and licorice-spicy, supporting its relevance as an aroma-profile contributor in some non-agarwood oils.
Measured: relative abundance
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedNo constituent-specific dermal limit, IFRA standard, or phototoxicity paper was located in the reviewed public sources.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Current activity literature is mostly computational or mixed-oil work, so consumer-facing copy should avoid implying validated therapeutic effects for isolated alpha-copaen-11-ol.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
predicted alpha amylase binding
A Sabina chinensis essential-oil paper reported alpha-copaen-11-ol among the better-scoring docked constituents against alpha-amylase, but the biological assay was run on the whole oil rather than isolated alpha-copaen-11-ol.
This experimental finding does not establish benefit, dose or safety in people using this blend.
predicted multitarget cancer pathway binding
A 2025 agarwood network-pharmacology paper included alpha-copaen-11-ol among 23 modeled phytocompounds in docking and target-network analysis related to cancer pathways, but the paper did not establish constituent-specific in vivo efficacy.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (6)
- No isolated human clinical studies specific to alpha-copaen-11-ol were located in the reviewed public sources.
- The constituent-specific mechanism literature is dominated by docking and network-pharmacology papers rather than direct cell or animal testing of isolated alpha-copaen-11-ol.
- Constituent-specific sensitization, dermal-limit, and phototoxicity data were not located in the reviewed public sources.
- Re-verification pass (2026-07-13, 2 searches): no IFRA/Tisserand & Young/EU Annex III/peer-reviewed dermal limit, sensitization, or phototoxicity data for alpha-copaen-11-ol was located. The existing dermal_limit_pct (20) and sensitizing (true) values remain unsourced placeholders and dermal_limit_verified is correctly left false; these values were left unchanged (not corrected or newly verified) pending a citable source, per policy of not guessing or fabricating.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.